Warren Center For Neuroscience Drug Discovery

Researchers at the Warren Center for Neuroscience Drug Discovery, a clinical stage biotech within the Vanderbilt University School of Medicine Basic Sciences, have detailed the successful drug discovery of a Phase I Single Ascending Dose clinical trial of VU319, a drug for memory loss in people with Alzheimer’s disease and schizophrenia. Read More

AdvancED spent it's first official year leveraging the collaborative potential of three university functions: online and lifelong learning, pedagogical support and educational technology. Look back at 2024's successes and milestones. Read More

The Center for Technology Transfer and Commercialization has honored five faculty members as 2024 Master Innovators for their groundbreaking research and transformative innovations. These pioneers, recognized for achievements spanning patents, startups and impactful technologies, exemplify Vanderbilt's dedication to translating academic excellence into societal advancements. Read More

The Dare to Grow campaign, which was launched publicly in spring 2023, has eclipsed its $3.2 billion fundraising goal 20 months ahead of its target date of June 30, 2026, underscoring the generosity of donors, widespread enthusiasm for the university’s vision and boundless potential for the future. The news is both a celebration and a call to action as Vanderbilt looks ahead to deepening its impact in Nashville, across the nation and around the world. Read More

Led by Craig W. Lindsley, Vanderbilt drug discovery experts set out to develop a backup drug candidate to improve memory loss in people with Alzheimer’s disease. Read More

See some of the bold and collaborative actions Vanderbilt University accomplished this year an innovator and leader in solving the world’s most pressing challenges. Read More

On October 17, 2022, Vanderbilt University launched “Discovery Vanderbilt” to embolden faculty, students and staff to pursue innovative ideas through disciplined, rigorous inquiry. Led by Provost Cybele Raver, the university committed $80 million in the effort—and invested $50 million in the first year alone. Read More

Join the next Lab-to-Table conversation, “Beyond Addiction: Therapeutic Developments and Societal Impact” on Jan. 24 at 11:30 a.m. CT. Read More

The School of Medicine Basic Sciences and the Office of the Vice Provost for Research and Innovation launch the Innovation Ignition Fund. This pilot program offers up to $500,000 in funding and drug development mentorship from Vanderbilt scientists with expertise in translational research. Read More

In just over two years, a Vanderbilt-Neumora collaboration has led to the Phase 1 clinical trial of a treatment for schizophrenia spectrum disorders, which affect 3.7 million adults in the United States. This is the third chemical compound discovered at the Warren Center for Neuroscience Drug Discovery to reach Phase 1 clinical trials.     Read More

Vanderbilt has announced the addition of the Warren Center for Neuroscience Drug Discovery into Discovery Vanderbilt as well as an initiative within the Dare to Grow campaign to inspire philanthropy with a one-to-one match for gifts of $100,000 or more. Read More

Biomedical engineer David Merryman and Warren Center for Neuroscience Drug Discovery director Craig Lindsley have developed a new drug that treats PAH, a type of high blood pressure that affects arteries in the lungs and in the heart, without serious neurological side effects. Read More

Kristen Gilliland, who lost her son to an accidental overdose, and the Warren Center for Neuroscience Drug Discovery premiered the documentary Speaking Through Me to educate teens on substance use and mental illness prevention. Read More

Stronger than at any other time in our history, we are positioned to do more than just meet the challenges of our times. We have what it takes to thrive and lead—to define and become the great university of this century. Read More

Craig W. Lindsley, University Distinguished Professor of Pharmacology, Biochemistry and Chemistry, who holds the William K. Warren, Jr. Chair in Medicine, was recently announced as a 2022 fellow of the American Society for Pharmacology and Experimental Therapeutics for his demonstrated excellence and contributions to pharmacology and to the ASPET organization. Read More

Warren Center for Neuroscience Drug Discovery lead researchers discover a therapy that may treat memory loss and slow the progression of Alzheimer’s disease. Read More

The National Institute of Mental Health has awarded a $3.4 million grant to professor Thilo Womelsdorf to study the underlying mechanisms of action for potential drugs to regulate cognitive function and brain network activity affected in schizophrenia without debilitating side effects. Read More

Prothena and the Warren Center for Neuroscience Drug Discovery have entered into a collaborative research agreement to develop new small molecule therapeutics for the treatment of Alzheimer’s disease in individuals with Down syndrome. Read More

Body-made cannabinoids that fine tune hunger signals in the brain have been mapped, with implications for helping those with deadly feeding-related illnesses Read More

Colleen Niswender, associate professor of pharmacology and director of molecular pharmacology for the Warren Center for Neuroscience Drug Discovery, was awarded the ASPET Scientific Achievement Award in Drug Discovery and Development for her work in the development of novel treatments for neurological and psychiatric disorders. Read More